Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Adagene Inc. (Nasdaq: ADAG) has announced upcoming poster presentations at the SITC 39th Annual Meeting in Houston, scheduled for November 6-10, 2024. The presentations will focus on Muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody®.
Two posters will be presented on November 9:
- Abstract 506: Comparing the clinical therapeutic index of Muzastotug to its unmasked form (ADG116) as monotherapy or combined with anti-PD-1 therapy.
- Abstract 744: Phase 1b/2 study of Muzastotug combined with Pembrolizumab in advanced/metastatic MSS CRCs.
Both posters will be viewable during lunch (12:15-1:45 PM CST) and at the poster reception (7:10-8:30 PM CST) at the George R. Brown Convention Center. The posters will also be available on Adagene's website.
Adagene Inc. (Nasdaq: ADAG) ha annunciato presentazioni di poster in programma al SITC 39° Congresso Annuale a Houston, previsto per il 6-10 novembre 2024. Le presentazioni si concentreranno su Muzastotug (ADG126), un SAFEbody® anti-CTLA-4 mascherato.
Due poster saranno presentati il 9 novembre:
- Abstract 506: Confronto dell'indice terapeutico clinico di Muzastotug con la sua forma non mascherata (ADG116) come monoterapia o combinato con terapia anti-PD-1.
- Abstract 744: Studio di Fase 1b/2 di Muzastotug combinato con Pembrolizumab in CRC MSS avanzati/metastatici.
Entrambi i poster saranno visibili durante il pranzo (12:15-1:45 PM CST) e alla reception dei poster (7:10-8:30 PM CST) al George R. Brown Convention Center. I poster saranno anche disponibili sul sito web di Adagene.
Adagene Inc. (Nasdaq: ADAG) ha anunciado presentaciones de pósteres en la 39ª Reunión Anual del SITC en Houston, programada del 6 al 10 de noviembre de 2024. Las presentaciones se centrarán en Muzastotug (ADG126), un SAFEbody® anti-CTLA-4 enmascarado.
Se presentarán dos pósteres el 9 de noviembre:
- Abstract 506: Comparación del índice terapéutico clínico de Muzastotug con su forma desmascarada (ADG116) como monoterapia o combinado con terapia anti-PD-1.
- Abstract 744: Estudio de Fase 1b/2 de Muzastotug combinado con Pembrolizumab en CRC MSS avanzados/metastásicos.
Ambos pósteres estarán disponibles durante el almuerzo (12:15-1:45 PM CST) y en la recepción de pósteres (7:10-8:30 PM CST) en el George R. Brown Convention Center. Los pósteres también estarán disponibles en el sitio web de Adagene.
Adagene Inc. (Nasdaq: ADAG)는 2024년 11월 6일부터 10일까지 휴스턴에서 열리는 SITC 제39회 연례 회의에서 다가오는 포스터 발표를 발표했습니다. 발표는 Muzastotug (ADG126), 마스킹된 항-CTLA-4 SAFEbody®에 중점을 둡니다.
11월 9일에는 두 개의 포스터가 발표됩니다:
- Abstract 506: Muzastotug의 임상 치료 지수를 그 비마스킹 형태(ADG116)와 단독 요법으로 비교하거나 항-PD-1 요법과 병합합니다.
- Abstract 744: 진행성/전이성 MSS CRC에서 Pembrolizumab과 함께한 Muzastotug의 1b/2상 연구.
두 포스터 모두 점심시간(12:15-1:45 PM CST) 동안과 포스터 리셉션(7:10-8:30 PM CST)에서 George R. Brown Convention Center에서 볼 수 있습니다. 포스터는 Adagene 웹사이트에서도 확인할 수 있습니다.
Adagene Inc. (Nasdaq: ADAG) a annoncé de prochaines présentations d'affiches lors de la 39e Réunion Annuelle du SITC à Houston, prévue du 6 au 10 novembre 2024. Les présentations mettront l'accent sur Muzastotug (ADG126), un SAFEbody® anti-CTLA-4 masqué.
Deux affiches seront présentées le 9 novembre :
- Abstract 506 : Comparaison de l'index thérapeutique clinique de Muzastotug avec sa forme non masquée (ADG116) en monothérapie ou combinée avec une thérapie anti-PD-1.
- Abstract 744 : Étude de Phase 1b/2 de Muzastotug combiné avec Pembrolizumab dans les CRC MSS avancés/métastatiques.
Les deux affiches seront visibles pendant le déjeuner (12:15-1:45 PM CST) et lors de la réception des affiches (7:10-8:30 PM CST) au George R. Brown Convention Center. Les affiches seront également disponibles sur le site web d'Adagene.
Adagene Inc. (Nasdaq: ADAG) hat bevorstehende Posterpräsentationen auf dem SITC 39. Jahrestreffen in Houston angekündigt, das für den 6.-10. November 2024 geplant ist. Die Präsentationen konzentrieren sich auf Muzastotug (ADG126), ein maskiertes anti-CTLA-4 SAFEbody®.
Am 9. November werden zwei Poster vorgestellt:
- Abstract 506: Vergleich des klinischen therapeutischen Index von Muzastotug mit seiner unmaskierten Form (ADG116) als Monotherapie oder in Kombination mit einer anti-PD-1-Therapie.
- Abstract 744: Phase 1b/2 Studie von Muzastotug in Kombination mit Pembrolizumab bei fortgeschrittenen/metastatischen MSS CRCs.
Beide Poster werden während des Mittagessens (12:15-1:45 PM CST) und bei der Poster-Rezeption (7:10-8:30 PM CST) im George R. Brown Convention Center sichtbar sein. Die Poster werden auch auf der Website von Adagene verfügbar sein.
- Adagene is presenting research on its novel antibody-based therapy at a major immunotherapy conference
- The company is showcasing two different studies on its masked anti-CTLA-4 SAFEbody® Muzastotug (ADG126)
- Research includes comparison with unmasked form and combination therapy, potentially demonstrating improved efficacy
- None.
SAN DIEGO and SUZHOU, China, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced poster presentations at the upcoming SITC 39th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024.
Details include:
Deciphering Improved Clinical Therapeutic Index (TI) of Muzastotug (ADG126), a Masked Anti-CTLA-4 SAFEbody® over its Unmasked Form (ADG116) as Monotherapy or in Combination with anti-PD-1 Therapy
- Date: Saturday, November 9
- Lunch & Poster Viewing: 12:15–1:45 PM CST
- Poster Reception: 7:10-8:30 PM CST
- Onsite Location: George R. Brown Convention Center (Level 1, Exhibit Halls AB)
- Abstract Number: 506
Phase 1b/2, Multicenter Dose Escalation and Expansion Study of Muzastotug (ADG126, a Masked Anti-CTLA-4 SAFEbody®) in Combination with Pembrolizumab in Advanced/Metastatic MSS CRCs
- Date: Saturday, November 9
- Lunch & Poster Viewing: 12:15–1:45 PM CST
- Poster Reception: 7:10-8:30 PM CST
- Onsite Location: George R. Brown Convention Center (Level 1, Exhibit Halls AB)
- Abstract Number: 744
Both posters will be made available on the Publications page of the company’s website here.
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the vanguard of science.
Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies in tumor microenvironment, while minimizing on-target off-tumor toxicity in healthy tissues.
Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers.
For more information, please visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and Twitter.
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Safe Harbor Statement
This press release contains forward-looking statements, including statements regarding certain clinical results of ADG126, the potential implications of clinical data for patients, and Adagene’s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Investor & Media Contact:
Ami Knoefler
Adagene
650-739-9952
ir@adagene.com
FAQ
What is Adagene presenting at the SITC 39th Annual Meeting in 2024?
When and where will Adagene's (ADAG) poster presentations take place at SITC 2024?
What is the focus of Adagene's (ADAG) research being presented at SITC 2024?
